Acquisition by Taylor Stacy L of 85697 shares of Adaptive Biotechnologies subject to Rule 16b-3

ADPT Stock  USD 2.60  0.02  0.78%   
Slightly above 52% of Adaptive Biotechnologies' investor base is interested to short. The analysis of overall sentiment of trading Adaptive Biotechnologies Corp stock suggests that many investors are impartial at this time. Adaptive Biotechnologies' investor sentiment overview provides quick insight into current market opportunities from investing in Adaptive Biotechnologies Corp. The current market sentiment, together with Adaptive Biotechnologies' historical and current headlines, can help investors time the market. In addition, many technical investors use Adaptive Biotechnologies stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Adaptive Biotechnologies stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Adaptive daily returns and investor perception about the current price of Adaptive Biotechnologies Corp as well as its diversification or hedging effects on your existing portfolios.
  
Filed transaction by Adaptive Biotechnologies officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Adaptive insider trading alert for grant of common stock by Taylor Stacy L, SVP and General Counsel, on 8th of March 2023. This event was filed by Adaptive Biotechnologies with SEC on 2023-03-08. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Adaptive Biotechnologies' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Adaptive Biotechnologies' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Adaptive Biotechnologies Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Adaptive Biotechnologies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Adaptive Biotechnologies Historical Investor Sentiment

Investor biases related to Adaptive Biotechnologies' public news can be used to forecast risks associated with an investment in Adaptive. The trend in average sentiment can be used to explain how an investor holding Adaptive can time the market purely based on public headlines and social activities around Adaptive Biotechnologies Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Adaptive Biotechnologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Adaptive Biotechnologies and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Adaptive Biotechnologies news discussions. The higher the estimate score, the more favorable the investor's outlook on Adaptive Biotechnologies.

Adaptive Biotechnologies Fundamental Analysis

We analyze Adaptive Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptive Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptive Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Per Share

Cash Per Share Comparative Analysis

Adaptive Biotechnologies is currently under evaluation in cash per share category among related companies. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Adaptive Biotechnologies Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adaptive Biotechnologies stock to make a market-neutral strategy. Peer analysis of Adaptive Biotechnologies could also be used in its relative valuation, which is a method of valuing Adaptive Biotechnologies by comparing valuation metrics with similar companies.

Peers

Adaptive Biotechnologies Related Equities

SANASana Biotechnology   6.06   
0%
53.0%
ENVBEnveric Biosciences   3.33   
0%
29.0%
APLSApellis Pharmaceuticals   2.48   
0%
21.0%
RPRXRoyalty PharmaPlc   0.58   
0%
5.0%
RPHMReneo Pharmaceuticals   0.59   
5.0%
0%
VIRVir Biotechnology   1.11   
9.0%
0%
AVROAVROBIO   1.65   
14.0%
0%
KRYSKrystal Biotech   1.85   
16.0%
0%
BEAMBeam TherapeuticsInc   3.11   
27.0%
0%
CRBUCaribou Biosciences   3.27   
28.0%
0%
VERVVerve Therapeutics   4.36   
38.0%
0%
IKNAIkena Oncology   4.44   
38.0%
0%
LEGNLegend BiotechCorp   4.81   
42.0%
0%
ZURAZura Bio   4.89   
42.0%
0%
ELEVElevation Oncology   10.19   
89.0%
0%
HEPAHepion Pharmaceuticals   11.41   
100.0%
0%
When determining whether Adaptive Biotechnologies is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Adaptive Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Adaptive Biotechnologies Corp Stock. Highlighted below are key reports to facilitate an investment decision about Adaptive Biotechnologies Corp Stock:

Complementary Tools for Adaptive Stock analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Transaction History
View history of all your transactions and understand their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.56)
Revenue Per Share
1.179
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.17)
Return On Equity
(0.58)
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.